市場調査レポート
商品コード
1468582
梅毒検査市場:タイプ別、検査部位別、地域別、2024~2032年Syphilis Testing Market by Type (Primary and Secondary Syphilis, Latent and Tertiary Syphilis), Location of Testing (Laboratory Testing, Point-of-Care (POC) Testing), and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
梅毒検査市場:タイプ別、検査部位別、地域別、2024~2032年 |
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2~3営業日
|
世界の梅毒検査市場規模は2023年に12億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに19億米ドルに達し、2024~2032年の間に5.1%の成長率(CAGR)を示すと予測しています。性感染症(STD)の蔓延、流産の増加、医療セグメントにおける効果的な疾病診断・検査ソリューションに対するニーズの高まりが、市場を牽引する主要要因のひとつです。
梅毒は性感染症(STI)のひとつで、通常、性的接触によって引き起こされ、皮膚や粘膜の接触を通じて個人間で感染します。梅毒は、性器や口の直腸に痛みを伴わないただれとして始まる。治療せずに放置すると、脳、神経、血管、関節を損傷する三次梅毒の合併症を引き起こす可能性があります。現在では、迅速血漿反応検査(RPR)と性病検査(VDRL)が標準的な検査法として開業医に用いられています。これらのアプローチは、より良い治療のための早期発見を提供し、性感染症(STD)の蔓延と発症を緩和します。その結果、梅毒検査は、梅毒のタイプを診断し、その適切な治療法を特定するために、検査室やポイントオブケア(POC)センターで頻繁に使用されています。
STD治療に関する意識の高まりは、市場成長を促進する重要な要因の1つです。これに伴い、さまざまな国の政府と非政府組織(NGO)は、梅毒を含むSTDの予防と利用可能な治療法について一般大衆を啓発するキャンペーンを積極的に実施しています。その結果、梅毒迅速検査キットなどの梅毒検査キットの普及が促進され、市場の成長を後押ししています。これらのキットは、効果的な診断結果を伴う在宅検査を提供するため、タイムリーな意思決定が可能であり、これも市場成長に寄与しています。さらに、これらの検査キットはオンライン小売店や店舗内の薬局で手頃な価格帯で入手できるため、使用上の利便性が高く、市場成長に寄与しています。これとは別に、医療部門の大幅な改善と、効果的な代替治療を開始するための最近の研究開発(R&D)活動は、市場成長にプラスの影響を与えています。さらに、性感染症の検査に有利な医療償還政策が存在することも、市場成長に寄与しています。梅毒を含む性病の有病率の増加、無防備な性交渉の増加、効果的なスクリーニングプログラムの広範な実施、疾患の早期診断への重点的な取り組み強化などのその他の要因が、市場に明るい展望を生み出しています。
The global syphilis testing market size reached US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 1.9 Billion by 2032, exhibiting a growth rate (CAGR) of 5.1% during 2024-2032. The growing prevalence of sexually transmitted diseases (STDs), the increasing incidences of miscarriages, and the rising need for effective disease diagnosing and testing solutions in the healthcare sector represent some of the key factors driving the market.
Syphilis refers to a sexually transmitted infection (STI) that is usually caused by sexual contact and is spread amongst individuals through the skin or mucous membrane contact. It starts as a painless sore on the genitals and rectum of the mouth. If left untreated, it might trigger complications of tertiary syphilis, wherein the disease may damage the brain, nerves, blood vessels, and joints. At present, rapid plasma reagin (RPR) and venereal diseases research laboratory (VDRL) are standard testing practices that are being used by practitioners. These approaches provide early detection for better treatment and mitigate the spread and development of sexually transmitted diseases (STDs). As a result, syphilis testing is frequently used in laboratories and point-of-care (PoC) centers to diagnose the syphilis type and identify its proper treatment.
The increasing awareness regarding STD treatment represents one of the key factors driving the market growth. In line with this, governments of various nations, along with different non-governmental organizations (NGOs) are actively undertaking campaigns to sensitize the common mass regarding the prevention of STDs, including syphilis, and the available treatment options. This, in turn, is facilitating the adoption of syphilis testing kits, such as syphilis rapid test strips, which is favorably supporting the market growth. These kits offer at-home testing with effective diagnostic results, and thus timely decision-making, which is also contributing to the market growth. Additionally, the convenience of usage and the easy availability of these test kits at online retail stores and in-store pharmacies at affordable price points are contributing to the market growth. Apart from this, the considerable improvements in the healthcare sector and the recent research and development (R&D) activities to launch effective treatment alternatives are positively impacting the market growth. Moreover, the presence of favorable medical reimbursement policies for the testing of sexually transmitted infections is contributing to the market growth. Other factors, such as the increasing prevalence of STDs, including syphilis, rising incidences of unprotected sexual intercourse, the widespread implementation of effective screening programs, and an enhanced focus on the early diagnostic of the disease, are creating a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each segment of the global syphilis testing market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on type and location of testing.
Primary and Secondary Syphilis
Latent and Tertiary Syphilis
The report has also provided a detailed breakup and analysis of the syphilis testing market based on the type. This includes primary and secondary, and latent and tertiary syphilis. According to the report, primary and secondary syphilis represented the largest segment.
Laboratory Testing
Point-of-Care (POC) Testing
A detailed breakup and analysis of the syphilis testing market based on the location of testing has also been provided in the report. This includes laboratory and point-of-are (POC) testing. According to the report, laboratory testing accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for syphilis testing. Some of the factors driving the North America syphilis testing market included the increasing prevalence of STDs, significant technological advancements, and extensive research and development (R&D) activities.
The report has also provided a comprehensive analysis of the competitive landscape in the global syphilis testing market. Detailed profiles of all major companies have also been provided. Some of the companies covered includes Abbott Laboratories, Becton Dickinson and Company, Bio-Rad Laboratories Inc., Danaher Corporation, DRG International Inc. (BioCheck Inc.), F. Hoffmann-La Roche AG, Siemens Healthineers AG (Siemens AG), Thermo Fisher Scientific Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.